Mark P. Ridgill

Statistics

Publications

Citations

714

H-Index

Active since

1993

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

MSD (UK) Limited (United Kingdom)

Mark P. Ridgill is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, medicinal chemistry, and ligand binding.

Publications per year

1993–2002

Publications

3-[[4-(4-Chlorophenyl)piperazin-1-yl]methyl]-1H-pyrrolo[2,3-b]pyridine: An Antagonist with High Affinity and Selectivity for the Human Dopamine D4 Receptor

Janusz J. Kulagowski, Howard B. Broughton, Neil R. Curtis et al. · Journal of Medicinal Chemistry · 1996 · 257 citations · Full text

Medicine, Pharmacology, Neurochemistry +4

Biological Profile of L-745,870, a Selective Antagonist with High Affinity for the Dopamine D4 Receptor

Smita S. Patel, Stephen B. Freedman, Kerry L. Chapman et al. · Journal of Pharmacology and Experimental Therapeutics · 1997 · 166 citations

Medicine, Medicinal Chemistry, Pharmacology +17

L-745,870, a Subtype Selective Dopamine D4 Receptor Antagonist, Does Not Exhibit a Neuroleptic-Like Profile in Rodent Behavioral Tests

Linda J. Bristow, Neil Collinson, Gina P Cook et al. · Journal of Pharmacology and Experimental Therapeutics · 1997 · 105 citations

Medicine, Behavioral Sciences, Pharmacology +16

2-Aryl indole NK1 receptor antagonists: optimisation of the 2-Aryl ring and the indole nitrogen substituent

Kevin Dinnell, Gary G. Chicchi, Madhumeeta J Dhar et al. · Bioorganic & Medicinal Chemistry Letters · 2001 · 57 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +9

Synthesis and sar of 2- and 3-substituted 7-azaindoles as potential dopamine D4 ligands

Neil R. Curtis, Janusz J. Kulagowski, Paul D. Leeson et al. · Bioorganic & Medicinal Chemistry Letters · 1999 · 45 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

1–5 of 10